Prostate Cancer VL

Office Based Therapeutics - Focal Therapy - Under a Paradigm of Certainty LUGPA 2022 Presentation- Fernando Bianco

Details
At the 2022 Large Urology Group Practice Association (LUGPA) annual meeting, Fernando Bianco presented on office-based therapeutics - focal therapy: under a paradigm of certainty during optimizing Ambulatory Surgery Centers (ASC) utilization. Biography: Fernando J. Bianco, MD, Investor in-Chief, Urological Research Network, Miami, FL, Professor of Urology, NOVA Southeastern University, Hollywood,...

The Addition of Docetaxel to Radiotherapy and ADT in Nonmetastatic Unfavorable-Risk Prostate Cancer Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss The Journal of Clinical Oncology publication entitled, "Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial." This trial evaluated the treatment effect of adding docetaxel to ADT + radiation therapy on the primary end point of overall...

Aggressive Variant Prostate Cancer: Definition, Diagnosis, Treatment APCCC 2022 Presentation - Eric Small

Details
Eric Small presents a discussion on primary small cell prostate cancer and therapeutic approaches to consider in aggressive variant prostate cancer (AVPC) and small cell neuroendocrine prostate cancer (t-SCNC) patients. Biographies: Eric Small, MD, Doris and Donald Fisher Distinguished Professorship in Clinical Cancer Research; Stanford W. Ascherman and Norman R. Ascherman Endowed Chair, UCSF, Pro...

Emerging Therapies and Therapeutic Targets in Prostate Cancer - Mark Rubin

Details
Mark Rubin joins Alicia Morgans to discuss emerging therapies and emerging therapeutic targets in prostate cancer. Topics covered include types of resistance, epigenetic therapies, and EZH2 inhibitors. Dr. Rubin also shares his thoughts on how he sees molecular pathology impacting cancer care in the next decade. Biographies: Mark A. Rubin, MD, Professor, Principal Investigator, and Director of Dep...

MRI and Active Surveillance for Prostate Cancer - Robert Reiter

Details
Rob Reiter and Alicia Morgans discuss the use of MRI and active surveillance in prostate cancer treatment. Dr. Reiter explains how MRI is used to improve proper patient selection for active surveillance. He also discusses how he was an early adopter of MRI and how he incorporates an MRI-guided biopsy program in his practice. In conclusion, Dr. Reiter and Dr. Morgans agree it’s important to note th...

Outcomes of the ARASENS Trial by Metastatic Subtype - Bertrand Tombal

Details
In a conversation with Alicia Morgans, Professor Bertrand Tombal provides a synopsis of metastatic subtypes in the ARASENS trial outcomes. The ARASENS trial investigated the benefit of darolutamide by comparing ADT plus docetaxel and darolutamide versus a placebo group. Tombal and Morgans wrap up the conversation by acknowledging the pragmatic and effective treatment recommendations that resulted...

Immunotherapy and PARP Inhibitors in Biochemical Recurrent Prostate Cancer - Alexandra Sokolova

Details
Alexandra Sokolova joins Alicia Morgans to discuss her work on biochemical recurrent prostate cancer. Dr. Sokolova and her team at OHSU hypothesize that a combination of durvalumab and olaparib will result in a deeper remission, delay the need for ADT, and improve the quality of life for patients who have a shorter PSA doubling time and a higher risk of developing metastasis. Biographies: Alexandr...

How Does the Data from the PEACE-1, ARASENS and ENZAMET Studies Inform Clinical Practice? - Karim Fizazi

Details
Karim Fizazi and Alicia Morgans discuss the latest ENZAMET updates shared at ASCO 2022. Dr. Fizazi considers the data from the ENZAMET study within the context of findings from the PEACE-1 AND ARASENS trials. In considering the data from these studies, Dr. Fizazi concludes by sharing his treatment recommendations for patients with de novo high volume MET versus de novo low volume MET, as well as t...

The EMBARK Study: A Phase 3 Randomized Study of Enzalutamide Plus Leuprolide and Enzalutamide Monotherapy in High-Risk Nonmetastatic Hormone-Sensitive Prostate Cancer with Rising PSA After Local Thera...

Details
Stephen Freedland presents the manuscript entitled A Phase 3 Randomized Study of Enzalutamide Plus Leuprolide and Enzalutamide Monotherapy in High-Risk Nonmetastatic Hormone-Sensitive Prostate Cancer with Rising PSA After Local Therapy: EMBARK Study Design. The objective of EMBARK was to value the efficacy and safety of enzalutamide in combination with leuprolide acetate or monotherapy compared wi...

Novel Approaches in the Management of High-Risk Prostate Cancer - Ray Manneh Kopp

Details
The Scientific Director at the Society of Oncology and Hematology from del Cesar, Columbia, Ray Manneh Kopp joins Phillip Koo bringing a global perspective to a discussion on the novel approaches in the management of high-risk prostate cancer. They discuss the diagnosis criteria currently being used, the novelties in the diagnosis, and adjuvant alternatives in this disease. Biographies: Ray Manneh...
email news signup